FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:675-677 March 9, 1995 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Ovarian cancer is the leading cause of death from gynecologic tumors and the fourth most frequent cause of death from cancer in women.¹ At diagnosis, as many as 70 percent of women with the most common type of ovarian cancer, epithelial cancer, have advanced disease (stages III and IV).² Fewer than 20 percent of patients with advanced cancer are alive five years after the diagnosis.³

Cytoreductive, or debulking, operations have become an established part of the treatment of advanced epithelial ovarian cancer.^4,5 Although the operation has been used extensively, until now the survival benefit of debulking surgery itself has not . . . [Full Text of this Article]

Rationale for Surgery

Definition of Terminology

The Retrospective Experience

The Limitations of Debulking

Differentiating Unresectable Tumors from Unresected Tumors

A Positive Prospective Trial

Words of Caution

References

Related Letters:

Interval Cytoreduction in Ovarian Cancer
Kehoe S., Shafi M., Luesley D., Neijt J.P., Cannistra S. A., van der Burg M. E.L., Buyse M., Pecorelli S.
Extract | Full Text  
N Engl J Med 1995; 333:254-255, Jul 27, 1995. Correspondence

This article has been cited by other articles:

• Bonnefoi, H., A'Hern, R. P., Fisher, C., Macfarlane, V., Barton, D., Blake, P., Shepherd, J. H., Gore, M. E. (1999). Natural History of Stage IV Epithelial Ovarian Cancer. JCO 17: 767-767 [Abstract] [Full Text]  
• Baron, A. T., Lafky, J. M., Boardman, C. H., Balasubramaniam, S., Suman, V. J., Podratz, K. C., Maihle, N. J. (1999). Serum sErbB1 and Epidermal Growth Factor Levels As Tumor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer. Cancer Epidemiol. Biomarkers Prev. 8: 129-137 [Abstract] [Full Text]  
• Neijt, J. P. (1996). New Therapy for Ovarian Cancer. NEJM 334: 50-51 [Full Text]  
• Kehoe, S., Shafi, M., Luesley, D., Neijt, J.P., Cannistra, S. A., van der Burg, M. E.L., Buyse, M., Pecorelli, S. (1995). Interval Cytoreduction in Ovarian Cancer. NEJM 333: 254-255 [Full Text]